CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today presented detailed results from the 52-week double-blind period of the global RISE UP Phase 3 trial of mitapivat, an oral pyruvate kinase (PK) activator, in patients aged…
Bank of Spain-regulated card issuer combines human-led and agentic AI pentesting to surface business logic risk and meet regulatory traceability requirements Bank of Spain-regulated card issuer combines human-led and agentic AI pentesting to surface business logic risk and meet regulatory traceability requirements
Þann 12. mars 2026 var tilkynnt um undirritun Sýnar hf. (Sýn) og Ása hf. (Ása) á skilmálaskjali um kaup Ása á vef- og útvarpsmiðlum Sýnar. Frestur samkvæmt skilmálaskjalinu til að ljúka gerð endanlegs kaupsamnings og annarrar nauðsynlegrar skjalagerðar er nú liðinn án þess að kaupsamningur hafi verið undirritaður. Samkomulag um einkarétt Ása til samningaviðræðna er…
